Resmed, Inc. (RMD) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Tanker struck by projectile in Strait of Hormuz
Needham & Company Upgrades ResMed (RMD) to Buy
January 23, 2015 6:25 AM ESTNeedham & Company upgraded ResMed (NYSE: RMD) from Hold to Buy with a price target of $77.00 following solid Q3 results as the product cycle drove faster growth.
Analyst Mike Matson comments, "RMD's F2Q15 revenue and EPS beat consensus. RMD's new products drove faster... More
